Search PubMed⌕ Search

Biomedical subjects

M Kuroda

Publications and source records attributed to M Kuroda.

At least 433 records · Page 24Linked to original sources
PubMed1986

[Cooperative phase II study of epirubicin (EPI) in bladder cancer, renal pelvic and ureteral tumors--Urological Cooperative Study Group of EPI].

A phase II study of a new anthracycline anti-cancer antibiotics, epirubicin (EPI), was undertaken in 71 patients with urothelial malignancies; 40 with advanced urothelial malignancies and 31 with superficial bladder cancer. Out of them 32 patients with advanced stage of urothelial cancer were evaluated for the systemic use of EPI, while 30 patients with superficial bladder cancer for intravesical use. Intravenous administration of this new anticancer antibiotic, at a dosage of 60 mg/m2 every three weeks, showed the response rate of 20.0% for advanced bladder cancer and 14.3% for renal pelvic and ureteral tumors. In cases of superficial bladder cancer, at a dosage of 60 mg/30 ml X 3 day every week in principal, the response rate was 66.7%. Eight out of 30 patients showed complete disappearance of the tumor. Twelve patients also showed more than 50% tumor regression. As for adverse effects no serious cardiotoxicity was demonstrated. Anorexia and other gastrointestinal side effects, such as nausea and vomiting, were also seen. Alopecia and myelosuppression were the major adverse effects among patients with systemic EPI administration. With intravesical use of EPI, cystitis syndrome was the major toxicity. However, no systemic side effects were noted in these cases. In conclusion, EPI was assumed to be effective for the treatment of advanced urothelial tumors and superficial bladder cancer.

Aged↗
PubMed1986

[Analysis of HLA-CW 3 antigens].

HLA-CW3 antigen was serologically analyzed by using antisera including defined at 9th International Histocompatibility Workshop (9th IHW) and panel cells from Japanese. On microcytotoxicity tests, the reaction patterns of these antisera against CW3 positive panel cells are divided into three groups. It was thought that the those three different patterns of the reaction could be the reflection of three new antigens, CW3.1, CW3.2, and CW3.3. This thought was verified by population as well as family studies. In population study using random and family panels, CW3.1 showed strong linkage disequilibrium with B35 and BW62, whereas CW3. 2 with BW60, BW61, and B13. In family study, CW3.1 and CW3.2 were inherited independently in two families. CW3.3 appeared to be identical with CX46 defined at 8th Japan Histocompatibility Workshop.

Adult↗
PubMed1985

Change of actin isomers during differentiation of smooth muscle.

Changes of actin isomers during development and differentiation of chicken gizzard were investigated by polyacrylamide gel electrophoresis. The two-dimensional gel electrophoresis with SDS-polyacrylamide gels in the presence of urea as the second dimension clearly separated three actin isomers which appear during development of the smooth muscle. The three actin isomers change the relative concentrations during development as follows: gizzard-type gamma-actin begins to be synthesized late on the 7th day of embryogenesis and increases in amount until hatching, nonmuscle-type gamma-actin exists only at earlier stages (before 15 days of embryogenesis), and the amount of beta-actin increases in proportion to the decrease of nonmuscle type gamma-actin, the amount of nonmuscle actin in gizzards then becoming constant. Actin composition of gizzard before 7 days of embryonic age was nonmuscle type and consisted of beta-actin and nonmuscle-type gamma-actin. These observations indicate that developmental process of gizzard smooth muscle cells are classified as three stages: nonmuscle, intermediate and smooth muscle stages.

Actins↗
PubMed1985

Association of chicken pectoralis muscle phosphorylase with the Z-line and the M-line of myofibrils: comparison with 'amorphin', the amorphous component of the Z-line.

By immunofluorescence technique, glycogen phosphorylase, one of the soluble glycolytic enzymes, was shown to be localized in the Z-line of chicken pectoralis muscle myofibrils, in addition to the M-line, as previously reported by Heizmann, C.W. and Eppenberger, H.M. (Heizmann, C.W. and Eppenberger, H.M. (1978) J. Biol. Chem. 253, 270-277). After extraction of thick filaments by a solution containing pyrophosphate and high salt (Hasselbach-Schneider solution), or after extraction of thin and thick filaments by a solution containing 0.6 M KI, phosphorylase still remained in the Z-line. Amorphin (Mr 85 000) was reported by Chowrashi, P.K. and Pepe, F.A. (Chowrashi, P.K. and Pepe, F.A. (1982) J. Cell Biol. 94, 565-573) as a new Z-line amorphous component. The amino acid composition of amorphin reported by them was very similar to that of phosphorylase b reported by Heizmann and Eppenberger. The partially purified 85 kDa protein, according to Chowrashi and Pepe, showed cross-reactivity to anti-phosphorylase serum and phosphorylase activity. Although amorphin was reported to be eluted from DEAE-column chromatography around the gradient of 0.5 M KCl, little protein was eluted around 0.5 M KCl in our experiments, and the 85 kDa protein which we identified as phosphorylase b was eluted around 0.2 M KCl. Hence, it should be said that the major 85 kDa protein extracted according to Chowrashi and Pepe was phosphorylase b.

Animals↗
PubMed1985

Genetic manipulation of membrane phospholipid composition in Escherichia coli: pgsA mutants defective in phosphatidylglycerol synthesis.

Unique mutants of Escherichia coli K-12, defective in phosphatidylglycerol synthesis, have been isolated from a temperature-sensitive strain incubated at its nonpermissive temperature. The parent strain had excess phosphatidylglycerol by harboring both the pss-1 allele [coding for a temperature-sensitive phosphatidylserine synthase (EC 2.7.8.8)] and the cls- allele (responsible for a defective cardiolipin synthase). The newly acquired mutations caused better growth at higher temperatures. One of the mutations (pgsA3) has been identified in the structural gene for phosphatidylglycerophosphate synthase [glycerophosphate phosphatidyltransferase (EC 2.7.8.5)]. Phospholipid compositions of these mutants were remarkable; phosphatidylethanolamine was the sole major lipid. In media with low osmotic pressures, these cells grew more slowly than the wild-type cells. They grew normally without recovering from the phospholipid abnormality in media appropriately supplemented with sucrose and MgCl2. Formation of cardiolipin and phosphoglycerol derivatives of membrane-derived oligosaccharides was reduced in a pgsA3 mutant. E. coli strains having the pgsA3, pss-1, and cls- mutations, either individually or in combination, constitute an empirical system in which the molar ratio of three major membrane phospholipids can be variously altered.

Cardiolipins↗
PubMed1985

Melanocytes in odontogenic keratocyst.

Melanocytes in odontogenic keratocyst (OKC) were studied histopathologically. As a result, melanocytes were observed within the basal layer of lining epithelium in five of 47 cases with OKC, with the overall prevalence being 10.6 per cent. Although no conclusion could be drawn from the present examination as to the origin of melanocytes in OKC, its possible histogenesis was discussed.

Adolescent↗
PubMed1985

Impaired metabolism of guanidinoacetic acid in uremia.

In order to investigate the guanidinoacetic acid (GAA) metabolism in uremia, we have measured serum guanidino compounds in patients with chronic renal failure (CRF) in comparison with normal subjects, and the renal content of GAA and glycine amidinotransferase (GAT) activity in the kidney of experimental CRF rabbits. Serum concentrations of guanidinosuccinic acid (GSA) and methylguanidine (MG) in the patients with CRF were higher than those in the normal subjects, as well as serum urea nitrogen (BUN) and creatinine (Cr) levels. The serum GAA levels were however, significantly lower and showed a tendency to decrease inversely with the elevation of BUN in the patients with CRF under conservative therapy. On the contrary, in the patients under maintenance hemodialysis (MHD) therapy, the serum GAA level did not decrease in spite of the elevation of BUN. Four anephric patients under MHD therapy showed a level of serum GAA similar to the other MHD patients. In the CRF rabbits, the renal GAA content was significantly lower than in the sham-operated rabbits and showed an inverse correlation with BUN. Renal GAT activity was also significantly lower in the CRF rabbits, showing a positive correlation with serum GAA concentration and an inverse correlation with BUN. These results indicate that renal GAT activity decreases as the BUN level rises in the course of renal damage, resulting in lower concentration of serum GAA in the uremic state; in a more advanced stage of renal failure, the inability of the kidney to synthesize GAA may be compensated by other organ(s). Some dialyzable substances which might inhibit renal GAT activity may also be present.

Adult↗
PubMed1985

Serum antioxidant activity in uremic patients.

Serum antioxidant activity (AOA) was examined in 35 healthy subjects and 111 patients with chronic renal failure (CRF), consisting of 13 patients in the predialysis stage, 11 requiring the start of regular dialysis therapy (RDT) and 87 undergoing RDT. Serum AOA was determined by assaying serum activity to inhibit malondialdehyde (MDA) generation. AOA levels were significantly lower in CRF patients, and the lowest levels were noticed in patients with uremic symptoms requiring the start of RDT. These levels were restored to a subnormal level during RDT. Defective serum AOA appears to be an endogenous metabolic consequence in uremia. Sera with low AOA tended to show high MDA levels, indicating that patients with low serum AOA were susceptible to cellular injury by lipid peroxidation. It is proposed that defective serum AOA may contribute to a certain uremic toxicity through peroxidative cell damage.

Adult↗
PubMed1985

[The clinical evaluation of hochuekkito for symptoms of malignant neoplasm patients].

Hochuekkito was administered in 2.5 g doses three times a day to 162 patients who complained of anorexia or lassitude because of genitourinary cancer. The efficacy rate was 63.0%. The rate of effectiveness on anorexia was 48.4% and that on lassitude was 36.6%. Side effects were observed in 12 patients (7.4%), but most of them were mild gastrointestinal disorders. No severe adverse effects were noted.

Adult↗